Cohance Lifesciences Ltd.
NSE: COHANCECohance Lifesciences Ltd.: A 30-second snapshot
Cohance Lifesciences (Rs 423.20) is a pharma smallcap that has declined 60.73% over the past year and sits 62.25% below its 52-week high, though it has recovered 19.7% over the past 3 months following the high-profile appointment of a new CEO. Revenue grew 77.3% over 5 years, but earnings contracted 70.3% over the same period, leaving a profit margin of 5.62% alongside a debt-to-equity of 11.49 that is rising. The trailing PE of 90.04 -- the highest in the pharma peer group -- implies the market is pricing a substantial earnings recovery.
P/E
90.0
Forward P/E
58.7
ROE
—
Debt / Equity
11.49
Profit Margin
+5.6%
Div. Yield
—
5Y ROE > 15%
3/5
5Y FCF > 0
4/5
Quality
36/100
News
8 headlines · 7 positive · 0 negative
Cohance Lifesciences share price surges 37% in two days on appointment of new CEO - Mint
Mint
Cohance Lifesciences hits 20% upper circuit: Why the stock rising today? - India Today
India Today
Cohance Lifesciences share price soared 20% today; here's why - Business Today
Business Today
Third-worst performing smallcap stock of 2026 gets a big name as CEO; Shares jumps 20% - CNBC TV18
CNBC TV18
Cohance Lifesciences shares skyrocket 20% on hiring former Cipla CEO Umang Vohra - The Economic Times
The Economic Times
Recent context
- ·Cohance shares surged approximately 37% over two sessions in late April 2026 after the company appointed Umang Vohra -- former CEO of Cipla -- as its new CEO, drawing coverage from Mint, Economic Times, CNBC TV18, and India Today.
- ·CNBC TV18 noted the stock was among the third-worst performing smallcap stocks of 2026 prior to the CEO announcement, contextualising the sharp move as a recovery from deeply depressed levels.
- ·Despite the positive news flow, the stock price at Rs 423.20 remains well below the single identified resistance level at Rs 514.90, with near-term support levels at Rs 355.05, Rs 303.05, and Rs 292.50.
Strengths
- +Revenue scale expanded 77.3% over 5 years, indicating top-line growth in the underlying contract-pharma business even as margins compressed.
- +FCF was positive in 4 of the last available years, suggesting the business has generated cash intermittently despite the earnings contraction.
- +The 3-month price recovery of 19.7% has moved the stock above its 50-DMA (Rs 360 vs current Rs 423.20), and RSI of 50.6 is in neutral territory with no overbought condition.
- +9 analysts cover the stock with a mean rating of 2.33 on a 1-5 scale (lower = more constructive), indicating active institutional research attention.
Weaknesses
- −Debt-to-equity of 11.49 with a rising debt trend and 70.3% earnings contraction over 5 years represents acute balance-sheet and profitability stress for a non-bank pharma company.
- −The stock is 30.2% below the 200-DMA (Rs 606.49) and 62.25% below its 52-week high, reflecting a prolonged downtrend; the 3-month bounce has not reversed the multi-year price damage.
- −Trailing PE of 90.04 is the highest in the peer group (Cipla: 29.8, Dr. Reddy's: 26.5, Sun Pharma: 41.3), pricing in an earnings recovery whose timeline and magnitude are uncertain against a 5-year earnings contraction.
- −Quality score of 27 and consistency score of 16 rank the stock 4th of 6 in the pharma peer group; ROE data is unavailable, limiting the ability to assess return-on-capital quality.
Open questions
- ?Can the incoming CEO structurally reduce the debt-to-equity (currently 11.49) and improve the profit margin (currently 5.62%), and over what timeframe has management communicated a path to do so?
- ?Does the 77.3% revenue growth over 5 years reflect durable contract-manufacturing relationships, or was it driven by one-time deals that have since compressed earnings?
- ?How does Cohance's business model differ from peers like Cipla and Dr. Reddy's that carry far lower D/E ratios and more stable earnings trajectories?
- ?Given that the forward PE of 58.67 already prices in a meaningful earnings recovery, what specific earnings milestones would validate the market's implied recovery timeline?
Peer comparison: Pharma
Ranks 4 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| COHANCE | Cohance Lifesciences Ltd.You're viewing | 90.0 | — | 27 |
| Industry avg | across 5 peers | 46.9 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.5 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.5 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.5 | +11.8% | 17 |
Technical state
Current price
₹423.20
SMA 50
₹360.00
SMA 200
₹606.49
RSI (14)
50.6 (neutral)
From 52w high
-62.3%
1Y return
-60.7%
3M return
+19.7%
50-DMA
Above
200-DMA
Below
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highDebt-to-equity of 11.49 is far above typical non-bank pharma norms; the debt trend is rising and earnings contracted 70.3% over 5 years, pointing to acute balance-sheet stress alongside deteriorating profitability.
- highCurrent price of Rs 423.20 is 62.25% below the 52-week high and 30.2% below the 200-DMA (Rs 606.49), reflecting a prolonged structural downtrend; the 3-month recovery of 19.7% has not yet closed the gap to the 200-DMA.
- highRevenue grew 77.3% over 5 years while earnings declined 70.3% over the same period; profit margin stands at 5.62% and the quality score of 27 ranks 4th of 6 in the pharma peer group, flagging severe operating-cost pressure relative to top-line growth.
- mediumTrailing PE of 90.04 is the highest among the 6 peer-group stocks (peers range 26.5-72.5); forward PE of 58.67 implies a significant earnings recovery already priced in, against a 5-year earnings contraction backdrop.
Cross-section contradictions
- News sentiment is strongly positive (7 of 8 articles positive, 0 negative), driven by the appointment of former Cipla CEO Umang Vohra, and the stock is up 19.7% over 3 months -- yet 5-year earnings declined 70.3% and D/E stands at 11.49, making the near-term price optimism diverge sharply from the underlying multi-year operating trend.
- The stock carries the highest trailing PE (90.04) in its pharma peer group while simultaneously ranking 4th of 6 on quality score -- a combination where premium valuation and below-median quality coexist.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 17 May 2026 · rotates through NIFTY 500 every ~5 days